Weight loss injection claims: separating evidence from noise

What the trials measured — and what that means for you

The headline figures cited most often come from NICE-reviewed randomised controlled trials. In SURMOUNT-1, published in the New England Journal of Medicine, adults taking tirzepatide 15mg alongside a reduced-calorie diet and increased activity lost around 20–21% of body weight on average over 72 weeks. The STEP 1 trial for semaglutide 2.4mg reported around 15% average weight loss over 68 weeks in a similar population.

Those are averages across thousands of participants. Some people lost considerably more; others lost less. The trials required participants to maintain lifestyle changes throughout, which is part of the treatment protocol, not a footnote. Presenting either figure as a guaranteed personal outcome is misleading, and no responsible clinician would do so.

SURMOUNT-5, a head-to-head comparison published in 2025, found tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks. That comparison matters for clinical decision-making, but it does not make one medicine universally superior, the right choice depends on individual circumstances, health history and tolerability, which is exactly what a prescriber assesses.

You can explore the wider picture of how these treatments work on the weight loss injection overview page.

Claims the evidence does not support

The MHRA has stated explicitly that GLP-1 medicines are not assessed for quick or cosmetic weight loss. That matters because a significant volume of online content frames these treatments as shortcuts for people who want to lose a few pounds before a holiday or drop a dress size fast. That is not what the clinical evidence examined, not what the medicines are licensed for, and not a safe basis for prescribing.

The licensed indication for both Mounjaro and Wegovy requires a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition such as high blood pressure, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. People outside these criteria are not appropriate candidates, and if you are weighing up whether you qualify, our guide to weight loss injections explains the eligibility criteria and what the clinical pathway looks like.

Social media content sometimes presents dramatic individual transformations as typical results, or implies the medicines work independently of diet and activity. Neither holds up against the trial data. The participants who achieved the largest average reductions in SURMOUNT-1 were following a structured programme. The medicine reduced appetite; the lifestyle work determined how much of that advantage was converted into sustained fat loss.

If you have seen references to Ozempic for weight loss, it is worth knowing that semaglutide under that brand is licensed for type 2 diabetes in the UK, not weight management.

Side effects: the part of the claim often left out

Weight loss injection claims rarely lead with side effects. The clinical record does. Nausea, diarrhoea, constipation, vomiting and reflux are the most common, particularly in the weeks after starting or after a dose increase. For most people these settle; for some they are persistent enough to affect adherence or require a prescriber to adjust the plan.

In January 2026 the MHRA issued a Drug Safety Update for GLP-1 medicines flagging acute pancreatitis as a known but infrequent risk: severe, persistent abdominal pain that may radiate to the back warrants urgent medical attention. The MHRA Yellow Card scheme is how patients report suspected side effects, and doing so contributes to the ongoing safety picture for these medicines.

A prescriber also needs to know about medicines you already take. Tirzepatide slows gastric emptying, which can affect the absorption of oral contraceptives; women on the pill are advised to add a non-oral contraceptive method for the first four weeks of treatment and for four weeks after each dose increase, and our page on weight loss injection risks and considerations goes into further detail on interactions like this. This is the kind of detail that only surfaces through a proper clinical assessment, not a quick online order.

For a fuller look at what these medicines cost through a private clinic, the weight loss injection cost guide puts the pricing context in one place.

How to make a genuinely informed decision

The decision worth making is not whether the claims sound appealing. It is whether, given your health picture, these medicines are clinically appropriate, and whether the provider offering them is doing so safely.

Prescription-only medicines require a prescription for a reason. A prescriber reviewing your full medical history, current medicines, BMI and weight-related conditions is doing the work that makes treatment appropriate and monitored, and if you are researching a specific option, the Mounjaro injection for weight loss page covers how that medicine works and what to expect. That process cannot be skipped without undermining the safety record those trial figures were built on.

At nume, every consultation is read by a GPhC-registered Independent Prescriber on the day it is submitted. If treatment is clinically suitable, it is dispensed from our own GPhC-registered pharmacy and arrives the next working day in plain, unbranded packaging via DPD, tracked to your door. Nothing about that process is rushed; the same-day review is about efficiency, not cutting corners.

If you are not sure which treatment might suit your situation, the treatment options page sets out what is currently available and what each involves. Our FAQs cover the questions our prescribers hear most often, and the clinical team profile gives you a sense of who is reviewing your case.

If you have read enough to want a clinical view on your own situation, you can start your free consultation at any point.